Gastroenterology strain | Antibiotic associated diarrhea – Prevention
Characteristics
DAILY DOSAGE IN CLINICAL STUDY
100M/5drops; 100M/tablet
FUNCTIONALITY
Antibiotic associated diarrhea – Prevention
Scientific support
Human clinical trials
Cimperman, L., G. Bayless, K. Best, A. Diligente, B. Mordarski, M. Oster, M. Smith, F. Vatakis, D. Wiese, A. Steiber, and J. Katz. A Randomized, Double-blind, Placebo-controlled Pilot Study of Lactobacillus Reuteri ATCC 55730 for the Prevention of Antibiotic-associated Diarrhea in Hospitalized Adults. Journal of Clinical Gastroenterology 45.9 (2011): 785-89.
Gastroenterology strain | Constipation
Characteristics
DAILY DOSAGE IN CLINICAL STUDY
100M/5drops; 100M/tablet
FUNCTIONALITY
C – Constipation
Scientific support
Human clinical trialsOjetti, V., G. Ianiro, A. Tortora, G. D’Angelo, T. A. Di Rienzo, S. Bibbo, A. Migneco, and A. Gasbarrini. The Effect of Lactobacillus Reuteri Supplementation in Adults with Chronic Functional Constipation: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Gastrointestinal and Liver Diseases 23.4 (2014): 387-91
Antipathogenic strain I Helicobacter pylori – Adjunct to standard eradication therapy
Characteristics
DAILY DOSAGE IN CLINICAL STUDY
100M/5drops; 100M/tablet
FUNCTIONALITY
HP – Helicobacter pylori – Adjunct to standard eradication therapy
Scientific support
Human clinical trial
Ainora, M.e., E.c. Nista, G. Vitale, V. Ojetti, V. Cesario, G. Gigante, L. Sparano, M.l. Novi, D. Roccarina, G. Cammarota, G. Gasbarrini, and A. Gasbarrini. Impact Of L. Reuterii Supplementation On Anti-H. Pylori Second Line Therapy-Related.”” Digestive and Liver Disease 40 (2008)
Francavilla, R., E. Lionetti, S. P. Castellaneta, A. M. Magista, G. Maurogiovanni, N. Bucci, A. De Canio, F. Indrio, L. Cavallo, E. Ierardi, and V. L. Miniello. Inhibition of Helicobacter Pylori Infection in Humans by Lactobacillus Reuteri ATCC 55730 and Effect on Eradication Therapy: A Pilot Study. Helicobacter 13.2 (2008): 127-34.
Imase, K., A. Tanaka, K. Tokunaga, H. Sugano, H. Ishida, and S. Takahashi. Lactobacillus Reuteri Tablets Suppress Helicobacter Pylori Infection–a Double-blind Randomised Placebo-controlled Cross-over Clinical Study. Journal of the Japanese Association for Infectious Diseases 81.4 (2007): 387-93.
Saggioro, A., M. Caroli, M. Pasini, F. Bortoluzzi, L. Girardi, and G. Pilone. Helicobacter Pylori Eradication with Lactobacillus Reuteri: A Double Blind Placebo-controlled Study. Dig Liver Dis 37.Suppl 1 (2005): S88.
Antipathogenic strain I Infectious diarrhea
Characteristics
DAILY DOSAGE IN CLINICAL STUDY
100M/5drops; 100M/tablet
FUNCTIONALITY
Infectious diarrhea
Scientific support
Human clinical trials
Aiello, R. A., M. Ali, M. Chiarenza, G. Carillio, G. Scandurra, and M. Caruso. Efficacy and Safety of Lactobacillus Reuteri ATCC 55730 in Preventing Acute Chemotherapy Induced Diarrhoea in Colon Cancer Patients Treated with DeGramont or Folfox Schedule. Annals of Oncology. S9 ed. Vol. 19. (2008).
Gastroenterology strain | Diarrhea in children
Characteristics
DAILY DOSAGE IN CLINICAL STUDY
100M/5drops; 100M/tablet
FUNCTIONALITY
Diarrhea in children
Scientific support
Human clinical trials
Francavilla R et al. Randomised clinical trial: Lactobacillus reuteri DSM 17938 vs. placebo in children with acute diarrhoea–a double-blind study. Aliment Pharmacol Ther 2012;36(4):363-9.
Gutierrez – Castrellon P et al., Diarrhea in Preschool Children and Lactobacillus reuteri: A Randomized Controlled Trial. Pediatrics 2014; 133(4):e904-9.
